{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T05:38:46Z","timestamp":1777181926847,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.prro.2023.05.004","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T05:56:44Z","timestamp":1685599004000},"page":"466-474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: 5-Year Toxicity and Biochemical Recurrence Results From a Prospective Trial"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7237-4237","authenticated-orcid":false,"given":"Jared A.","family":"Maas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael C.","family":"Dobelbower","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eddy S.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grant M.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rojymon","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rex A.","family":"Cardan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Popple","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey W.","family":"Nix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soroush","family":"Rais-Bahrami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John B.","family":"Fiveash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2023.05.004_bib0001","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.ijrobp.2006.10.050","article-title":"Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results","volume":"67","author":"Madsen","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.05.004_bib0002","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2016.02.014","article-title":"Stereotactic body radiation therapy for low and intermediate risk prostate cancer: Results from a multi-institutional clinical trial","volume":"59","author":"Hannan","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.prro.2023.05.004_bib0003","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ijrobp.2014.03.012","article-title":"Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer","volume":"89","author":"Kim","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.05.004_bib0004","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ijrobp.2010.11.054","article-title":"Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer","volume":"82","author":"King","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.05.004_bib0005","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1002\/cncr.26699","article-title":"Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: Preliminary results of a multi-institutional phase 1 feasibility trial","volume":"118","author":"McBride","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.prro.2023.05.004_bib0006","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3389\/fonc.2014.00240","article-title":"Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study","volume":"4","author":"Katz","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.prro.2023.05.004_bib0007","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.juro.2016.07.084","article-title":"Magnetic resonance imaging underestimation of prostate cancer geometry: Use of patient specific molds to correlate images with whole mount pathology","volume":"197","author":"Priester","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.prro.2023.05.004_bib0008","doi-asserted-by":"crossref","first-page":"406","DOI":"10.21037\/tau.2017.03.50","article-title":"Rais-Bahrami S. Co-registration of MRI and ultrasound: Accuracy of targeting based on radiology-pathology correlation","volume":"6","author":"Lai","year":"2017","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.prro.2023.05.004_bib0009","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ijrobp.2014.01.042","article-title":"Prostate stereotactic ablative radiation therapy using volumetric modulated arc therapy to dominant intraprostatic lesions","volume":"89","author":"Murray","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.05.004_bib0010","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/1748-717X-8-228","article-title":"Prostate stereotactic body radiotherapy with simultaneous integrated boost: Which is the best planning method?","volume":"8","author":"Tree","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.prro.2023.05.004_bib0011","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.radonc.2013.04.027","article-title":"Boosting imaging defined dominant prostatic tumors: A systematic review","volume":"107","author":"Bauman","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2023.05.004_bib0012","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.adro.2018.09.007","article-title":"Prostate stereotactic body radiation therapy with a focal simultaneous integrated boost: acute toxicity and dosimetry results from a prospective trial","volume":"4","author":"McDonald","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.prro.2023.05.004_bib0013","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1007\/s00330-011-2377-y","article-title":"ESUR prostate MR guidelines 2012","volume":"22","author":"Barentsz","year":"2012","journal-title":"Eur Radiol"},{"key":"10.1016\/j.prro.2023.05.004_bib0014","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ijrobp.2018.06.008","article-title":"Patient reported outcomes in NRG Oncology RTOG 0938, evaluating two ultrahypofractionated regimens for prostate cancer","volume":"102","author":"Lukka","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.05.004_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-032795","article-title":"Determining the minimal important differences in the International Prostate Symptom Score and Overactive Bladder Questionnaire: Results from an observational cohort study in Dutch primary care","volume":"9","author":"Blanker","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.prro.2023.05.004_bib0016","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.urology.2014.08.044","article-title":"Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form","volume":"85","author":"Skolarus","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.prro.2023.05.004_bib0017","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","article-title":"Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer","volume":"70","author":"Kuban","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.05.004_bib0018","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.294.10.1233","article-title":"Comparison of conventional-dose versus high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial","volume":"294","author":"Zietman","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.prro.2023.05.004_bib0019","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0360-3016(98)00091-1","article-title":"Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer","volume":"41","author":"Zelefsky","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.05.004_bib0020","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ijrobp.2017.07.021","article-title":"Conventional versus hypofractionated radiation therapy for localized or locally advanced prostate cancer: A systematic review and meta-analysis along with therapeutic implications","volume":"99","author":"Datta","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.05.004_bib0021","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2023.05.004_bib0022","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijrobp.2018.12.045","article-title":"Five-year outcomes of a phase 1 dose-escalation study using stereotactic body radiosurgery for patients with low-risk and intermediate-risk prostate cancer","volume":"104","author":"Zelefsky","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.05.004_bib0023","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.3390\/jcm10153396","article-title":"Non-adaptive MR-guided radiotherapy for prostate SBRT: Less time, equal results","volume":"10","author":"Sandoval","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.prro.2023.05.004_bib0024","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3390\/jpm13020233","article-title":"Large prostate volume does not negatively impact health-related quality of life in patients with prostate cancer treated with ultrahypofractionated stereotactic body radiotherapy","volume":"13","author":"Milecki","year":"2023","journal-title":"J Pers Med"},{"key":"10.1016\/j.prro.2023.05.004_bib0025","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.prro.2023.05.004_bib0026","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3389\/fonc.2014.00279","article-title":"A Phase II trial of stereotactic ablative body radiotherapy for low-risk prostate cancer using a non-robotic linear accelerator and real-time target tracking: Report of toxicity, quality of life, and disease control outcomes with 5-year minimum follow-up","volume":"4","author":"Mantz","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.prro.2023.05.004_bib0027","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: Results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2023.05.004_bib0028","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.euo.2022.02.005","article-title":"Local failure after prostate SBRT predominantly occurs in the PI-RADS 4 or 5 dominant intraprostatic lesion","volume":"6","author":"Gorovets","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.prro.2023.05.004_bib0029","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2018.05.040","article-title":"Multicenter trial of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: Survival and toxicity endpoints","volume":"102","author":"Meier","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.05.004_bib0030","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): Acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2023.05.004_bib0031","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2023.05.004_bib0032","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1186\/s12885-021-08281-x","article-title":"Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (MIRAGE): A phase III randomized trial","volume":"21","author":"Ma","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.prro.2023.05.004_bib0033","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1016\/j.ijrobp.2022.07.507","article-title":"Magnetic Resonance Imaging-Guided versus. Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer (MIRAGE): Primary endpoint analysis of a phase III randomized trial","volume":"114","author":"Kishan","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.05.004_bib0034","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1097\/RLU.0000000000004646","article-title":"Comparing the detection performance between multiparametric magnetic resonance imaging and prostate-specific membrane antigen PET\/CT in patients with localized prostate cancer: A systematic review and meta-analysis","volume":"48","author":"Wang","year":"2023","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.prro.2023.05.004_bib0035","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.radonc.2014.04.016","article-title":"Multi-modality functional image guided dose escalation in the presence of uncertainties","volume":"111","author":"Alber","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2023.05.004_bib0036","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13550-021-00844-0","article-title":"Short-duration dynamic 18F.DCFPyL PET and CT perfusion imaging to localize dominant intraprostatic lesions in prostate cancer: Validation against digital histopathology and comparison to 18F.DCFPyL PET\/MR at 120 minutes","volume":"11","author":"Yang","year":"2021","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.prro.2023.05.004_bib0037","first-page":"10817","article-title":"Stereotactic body radiation therapy with simultaneous integrated boost for prostate cancer: Does MRI-targeted biopsy alter the boost field?","volume":"28","author":"Fang","year":"2021","journal-title":"Can J Urol"},{"key":"10.1016\/j.prro.2023.05.004_bib0038","first-page":"e2524","article-title":"Stereotactic radiosurgery for prostate cancer following magnetic resonance imaging directed biopsy: A multidisciplinary approach with case examples","volume":"10","author":"Coker","year":"2018","journal-title":"Cureus"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850023001583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850023001583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:26:05Z","timestamp":1761819965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850023001583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1879850023001583"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2023.05.004","relation":{},"ISSN":["1879-8500"],"issn-type":[{"value":"1879-8500","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: 5-Year Toxicity and Biochemical Recurrence Results From a Prospective Trial","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2023.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}